Edition:
India

BioLine RX Ltd (BLRX.OQ)

BLRX.OQ on NASDAQ Stock Exchange Capital Market

1.04USD
12:51am IST
Change (% chg)

$-0.01 (-0.95%)
Prev Close
$1.05
Open
$1.08
Day's High
$1.08
Day's Low
$1.04
Volume
61,164
Avg. Vol
71,456
52-wk High
$1.38
52-wk Low
$0.80

Select another date:

Tue, Nov 21 2017

BRIEF-BioLine Rx Ltd Q3 ‍loss per ordinary share $0.07​

* BioLine Rx ltd - qtrly ‍loss per ordinary share $0.07​ Source text for Eikon: Further company coverage:

BRIEF-BioLineRX initiates phase 1b/2 trial for BL-8040 in gastric cancer under immunotherapy collaboration

* BioLineRX announces initiation of phase 1b/2 trial for BL-8040 in gastric cancer under immunotherapy collaboration

BRIEF-BioLineRx announces initiation of Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration

* BioLineRx announces initiation of Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration Source text for Eikon: Further company coverage:

BRIEF-Biolinerx announces regulatory submission of phase 3 registrational study for BL-8040 in stem cell mobilization

* Biolinerx announces regulatory submission of phase 3 registrational study for bl-8040 in stem cell mobilization

BRIEF-Biolinerx Q2 ‍loss per share $0.05​

* Qtrly ‍loss per share $0.05​ Source text for Eikon: Further company coverage:

BRIEF-Biolinerx announces additional investment from BVF Partners L.P.

* BiolineRx announces additional investment from BVF partners L.P.

BVF raises stake in biopharma firm BioLineRx to 24.9 pct

* Israeli biopharmaceutical firm BioLineRx said on Wednesday that BVF Partners, its largest shareholder, agreed to invest an additional $9.6 million in BioLineRx, raising its holding to 24.9 percent from 18.3 percent.

BRIEF-BiolineRx reports regulatory submissions of 3 Phase 1b trials for BL-8040 in combination with atezolizumab for solid tumors

* BiolineRx reports regulatory submissions of three phase 1b trials for BL-8040 in combination with atezolizumab for solid tumors

BRIEF-BioLine Rx reports Q1 loss per share $0.06

* BioLine Rx Ltd qtrly loss per share $0.06 Source text for Eikon: Further company coverage:

BRIEF-Biolinerx announces regulatory submission for phase 1B trial of BL-8040

* Biolinerx announces regulatory submission for phase 1B trial of BL-8040 in combination with atezolizumab in AML

Select another date: